All In Biotech

Drug Trial Radar · NCT07029412

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

A Phase 2a, Open-label, Exploratory Study to Evaluate Preliminary Efficacy of Subcutaneous MBX 1416 in Patients With Postbariatric Hypoglycemia (The STEADI Study)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Aug 26, 2025

Primary completion

Apr 18, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
MBX BiosciencesIndustry
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH

Conditions

  • Postbariatric Hypoglycemia

Interventions

  • MBX 1416 (INN imapextide)Drug

    A single subcutaneous injection of MBX 1416 at a low dose and a high dose approximately 2 weeks apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416.Time frame: The duration of the study will be approximately 67 days from screening to end of study (EoS) for any given participant

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • MBX Biosciences Investigational Site

    Aurora, Colorado

  • MBX Biosciences Investigational Site

    Morehead City, North Carolina

  • MBX Biosciences Investigational Site

    Knoxville, Tennessee

  • MBX Biosciences Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.